Evidence map›Paper›PMID 39488644›Full record

ArticleJournal of cancer research and clinical oncology2024

Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.

Tao Xu, Joseph S Dillon, Mary A Maluccio, Dawn E Quelle, Sarah H Nash, Hyunkeun Cho, Kristen E Limbach, Nicholas J Skill, Yvette Bren-Mattison, Michael A O'Rorke

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tao XuDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Joseph S DillonENETS Center of Excellence, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Mary A MaluccioDepartment of Surgery, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Dawn E QuelleENETS Center of Excellence, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Sarah H NashDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA.
Hyunkeun ChoDepartment of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA.
Kristen E LimbachDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.
Nicholas J SkillDepartment of Surgery, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Yvette Bren-MattisonDepartment of Surgery, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Michael A O'RorkeDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, USA. Michael-ororke@uiowa.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRenal and hematological toxicity are side effects and dose-limiting factors of Peptide Receptor Radionuclide Therapy (PRRT). We aimed to assess the changes in renal and hematological function and associations with survival in neuroendocrine tumor (NET) patients treated with PRRT.

methodsA retrospective cohort of 448 NET patients treated with either

resultsOf the 448 PRRT treated patients, 335 received

conclusionThere was no significant renal, but minor hematological toxicity, in patients treated with

Indexed as

Neuroendocrine TumorsOctreotideOrganometallic CompoundsReceptors, PeptideAdultAgedAged, 80 and overFemaleHematologic DiseasesHumansKidney DiseasesMaleMiddle AgedRadiopharmaceuticalsRetrospective StudiesUnited States90Y-octreotide, DOTA-Tyr(3)-lutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, PeptideHematological toxicityNeuroendocrine tumorsPeptide Receptor Radionuclide TherapyRenal toxicitySurvival

Identifiers

PMID39488644
PMCPMC11531437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.